<?xml version='1.0' encoding='utf-8'?>
<document id="28700519"><sentence text="Managing Drug-Drug Interaction Between Ombitasvir, Paritaprevir/Ritonavir, Dasabuvir, and Mycophenolate Mofetil."><entity charOffset="39-49" id="DDI-PubMed.28700519.s1.e0" text="Ombitasvir" /><entity charOffset="51-63" id="DDI-PubMed.28700519.s1.e1" text="Paritaprevir" /><entity charOffset="64-73" id="DDI-PubMed.28700519.s1.e2" text="Ritonavir" /><entity charOffset="75-84" id="DDI-PubMed.28700519.s1.e3" text="Dasabuvir" /><entity charOffset="90-111" id="DDI-PubMed.28700519.s1.e4" text="Mycophenolate Mofetil" /><pair ddi="false" e1="DDI-PubMed.28700519.s1.e0" e2="DDI-PubMed.28700519.s1.e0" /><pair ddi="false" e1="DDI-PubMed.28700519.s1.e0" e2="DDI-PubMed.28700519.s1.e1" /><pair ddi="false" e1="DDI-PubMed.28700519.s1.e0" e2="DDI-PubMed.28700519.s1.e2" /><pair ddi="false" e1="DDI-PubMed.28700519.s1.e0" e2="DDI-PubMed.28700519.s1.e3" /><pair ddi="false" e1="DDI-PubMed.28700519.s1.e0" e2="DDI-PubMed.28700519.s1.e4" /><pair ddi="false" e1="DDI-PubMed.28700519.s1.e1" e2="DDI-PubMed.28700519.s1.e1" /><pair ddi="false" e1="DDI-PubMed.28700519.s1.e1" e2="DDI-PubMed.28700519.s1.e2" /><pair ddi="false" e1="DDI-PubMed.28700519.s1.e1" e2="DDI-PubMed.28700519.s1.e3" /><pair ddi="false" e1="DDI-PubMed.28700519.s1.e1" e2="DDI-PubMed.28700519.s1.e4" /><pair ddi="false" e1="DDI-PubMed.28700519.s1.e2" e2="DDI-PubMed.28700519.s1.e2" /><pair ddi="false" e1="DDI-PubMed.28700519.s1.e2" e2="DDI-PubMed.28700519.s1.e3" /><pair ddi="false" e1="DDI-PubMed.28700519.s1.e2" e2="DDI-PubMed.28700519.s1.e4" /><pair ddi="false" e1="DDI-PubMed.28700519.s1.e3" e2="DDI-PubMed.28700519.s1.e3" /><pair ddi="false" e1="DDI-PubMed.28700519.s1.e3" e2="DDI-PubMed.28700519.s1.e4" /></sentence><sentence text="No drug-drug interaction study has been conducted to date for the combination of ombitasvir, paritaprevir/ritonavir, dasabuvir (3D), and mycophenolic acid (MPA)"><entity charOffset="81-91" id="DDI-PubMed.28700519.s2.e0" text="ombitasvir" /><entity charOffset="93-105" id="DDI-PubMed.28700519.s2.e1" text="paritaprevir" /><entity charOffset="106-115" id="DDI-PubMed.28700519.s2.e2" text="ritonavir" /><entity charOffset="117-126" id="DDI-PubMed.28700519.s2.e3" text="dasabuvir" /><entity charOffset="137-154" id="DDI-PubMed.28700519.s2.e4" text="mycophenolic acid" /><entity charOffset="156-159" id="DDI-PubMed.28700519.s2.e5" text="MPA" /><pair ddi="false" e1="DDI-PubMed.28700519.s2.e0" e2="DDI-PubMed.28700519.s2.e0" /><pair ddi="false" e1="DDI-PubMed.28700519.s2.e0" e2="DDI-PubMed.28700519.s2.e1" /><pair ddi="false" e1="DDI-PubMed.28700519.s2.e0" e2="DDI-PubMed.28700519.s2.e2" /><pair ddi="false" e1="DDI-PubMed.28700519.s2.e0" e2="DDI-PubMed.28700519.s2.e3" /><pair ddi="false" e1="DDI-PubMed.28700519.s2.e0" e2="DDI-PubMed.28700519.s2.e4" /><pair ddi="false" e1="DDI-PubMed.28700519.s2.e0" e2="DDI-PubMed.28700519.s2.e5" /><pair ddi="false" e1="DDI-PubMed.28700519.s2.e1" e2="DDI-PubMed.28700519.s2.e1" /><pair ddi="false" e1="DDI-PubMed.28700519.s2.e1" e2="DDI-PubMed.28700519.s2.e2" /><pair ddi="false" e1="DDI-PubMed.28700519.s2.e1" e2="DDI-PubMed.28700519.s2.e3" /><pair ddi="false" e1="DDI-PubMed.28700519.s2.e1" e2="DDI-PubMed.28700519.s2.e4" /><pair ddi="false" e1="DDI-PubMed.28700519.s2.e1" e2="DDI-PubMed.28700519.s2.e5" /><pair ddi="false" e1="DDI-PubMed.28700519.s2.e2" e2="DDI-PubMed.28700519.s2.e2" /><pair ddi="false" e1="DDI-PubMed.28700519.s2.e2" e2="DDI-PubMed.28700519.s2.e3" /><pair ddi="false" e1="DDI-PubMed.28700519.s2.e2" e2="DDI-PubMed.28700519.s2.e4" /><pair ddi="false" e1="DDI-PubMed.28700519.s2.e2" e2="DDI-PubMed.28700519.s2.e5" /><pair ddi="false" e1="DDI-PubMed.28700519.s2.e3" e2="DDI-PubMed.28700519.s2.e3" /><pair ddi="false" e1="DDI-PubMed.28700519.s2.e3" e2="DDI-PubMed.28700519.s2.e4" /><pair ddi="false" e1="DDI-PubMed.28700519.s2.e3" e2="DDI-PubMed.28700519.s2.e5" /><pair ddi="false" e1="DDI-PubMed.28700519.s2.e4" e2="DDI-PubMed.28700519.s2.e4" /><pair ddi="false" e1="DDI-PubMed.28700519.s2.e4" e2="DDI-PubMed.28700519.s2.e5" /></sentence><sentence text=" We here report the case of a hepatitis C virus-infected patient treated with 3D and MPA for vasculitis"><entity charOffset="85-87" id="DDI-PubMed.28700519.s3.e0" text="MPA" /></sentence><sentence text=" In light of the threat of drug-drug interaction, the concentration of MPA was measured before, during, and 15 days after the end of the 3D treatment"><entity charOffset="71-73" id="DDI-PubMed.28700519.s4.e0" text="MPA" /></sentence><sentence text=" Similar values were found at all 3 time points, thus indicating that there is probably no need to adapt MPA dosage to 3D"><entity charOffset="105-107" id="DDI-PubMed.28700519.s5.e0" text="MPA" /></sentence><sentence text="" /></document>